Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 22c; Boosts Buyback, FY13 Outlook
Tweet Send to a Friend
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q1 EPS of $0.68, $0.22 better than the analyst estimate of $0.46. Revenue for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
